Nanoplexed Poly I:C BO-112

Phase 1Biologic

JJonsson Comprehensive Cancer Center

Nanoplexed Poly I:C BO-112 is one of 88 biologic programs targeting Liver Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver CancerActive, not recruiting

Soft Tissue SarcomaActive, not recruiting

Liver CancerPhase 1

Active, not recruiting

Soft Tissue SarcomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

261 competitors in Liver Cancer

#DrugCompanyPhaseTrials

Nexavar

Bayer

Phase 3

35 2

Eloxatin

Teva

Phase 3

8 3

Adriamycin

Pfizer

Phase 3

7 4

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

14 5

Imjudo

AstraZeneca

Phase 3

3 6

Gemzar

Johnson & Johnson

Phase 3

2 7

Adriamycin

GGynecologic Oncology Group

Phase 3

11 8

Megace

Bristol-Myers Squibb

Phase 3

1 9

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

5 10

Zinecard

Pfizer

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Active, not recruiting

Soft Tissue Sarcoma

NCT04420975

Clinical

Trials by Indication[1]

Liver Cancer1 trial

BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer

Terminated·JJonsson Comprehensive Cancer Center·Phase 1·NCT04777708·1 enrolled

Soft Tissue Sarcoma1 trial

Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma

Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 1·NCT04420975·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Nanoplexed Poly I:C BO-112. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nanoplexed Poly I:C BO-112 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nanoplexed Poly I:C BO-112. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jonsson Comprehensive Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: JJonsson Comprehensive Cancer Center

Nanoplexed Poly I:C BO-112

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Liver Cancer1 trial

Soft Tissue Sarcoma1 trial

References

Drug Info

Quick Facts

Related News